Your browser doesn't support javascript.
loading
Multi-laboratory experiment PME11 for the standardization of phosphoproteome analysis.
Colomé, Núria; Abian, Joaquín; Aloria, Kerman; Arizmendi, Jesús M; Barceló-Batllori, Silvia; Braga-Lagache, Sophie; Burlet-Schiltz, Odile; Carrascal, Montse; Casal, J Ignacio; Chicano-Gálvez, Eduard; Chiva, Cristina; Clemente, Luis Felipe; Elortza, Felix; Estanyol, Josep M; Fernandez-Irigoyen, Joaquín; Fernández-Puente, Patricia; Fidalgo, María José; Froment, Carine; Fuentes, Manuel; Fuentes-Almagro, Carlos; Gay, Marina; Hainard, Alexandre; Heller, Manfred; Hernández, María Luisa; Ibarrola, Nieves; Iloro, Ibon; Kieselbach, Thomas; Lario, Antonio; Locard-Paulet, Marie; Marina-Ramírez, Anabel; Martín, Luna; Morato-López, Esperanza; Muñoz, Javier; Navajas, Rosana; Odena, M Antonia; Odriozola, Leticia; de Oliveira, Eliandre; Paradela, Alberto; Pasquarello, Carla; de Los Rios, Vivian; Ruiz-Romero, Cristina; Sabidó, Eduard; Sánchez Del Pino, Manuel; Sancho, Jaime; Santamaría, Enrique; Schaeffer-Reiss, Christine; Schneider, Justine; de la Torre, Carolina; Valero, M Luz; Vilaseca, Marta.
Affiliation
  • Colomé N; ProteoRed-ISCIII, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.
  • Abian J; ProteoRed-ISCIII, Instituto de Investigaciones Biomédicas de Barcelona, IIBB-CSIC/IDIBAPS, 08036 Barcelona, Spain.
  • Aloria K; ProteoRed-ISCIII, Proteomics Core Facility-SGIKER, University of the Basque Country (UPV/EHU), Leioa, Spain.
  • Arizmendi JM; Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.
  • Barceló-Batllori S; ProteoRed-ISCIII, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Braga-Lagache S; Department for BioMedical Research (DBMR), Proteomics and Mass Spectrometry Core Facility, University of Bern, CH-3010 Bern, Switzerland.
  • Burlet-Schiltz O; Proteomics and Mass Spectrometry of Biomolecules, Proteomics Infrastructure of Toulouse, Proteomics French Infrastructure, ProFI. Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, UPS, CNRS, Toulouse, France.
  • Carrascal M; ProteoRed-ISCIII, Instituto de Investigaciones Biomédicas de Barcelona, IIBB-CSIC/IDIBAPS, 08036 Barcelona, Spain.
  • Casal JI; ProteoRed-ISCIII, Centro de Investigaciones Biológicas-CSIC, Madrid 28040, Spain.
  • Chicano-Gálvez E; ProteoRed-ISCIII, Proteomics Unit, IMIBIC/UCO/HURS, IMIBIC Building Fl.3, 14004 Córdoba, Spain.
  • Chiva C; Proteomics Unit, Center for Genomics Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; ProteoRed ISCIII, Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain.
  • Clemente LF; ProteoRed-ISCIII, Proteomics Unit, Complutense University, 28040 Madrid, Spain.
  • Elortza F; ProteoRed-ISCIII, CIC bioGUNE, Proteomics Platform, Basque Research & Technology Alliance (BRTA), CIBERehd,Bizkaia Science and Technology Park, 48160 Derio, Spain.
  • Estanyol JM; ProteoRed-ISCIII, Scientific and Technological Centers (CCiTUB), University of Barcelona, 08036 Barcelona, Spain.
  • Fernandez-Irigoyen J; Proteored-ISCIII. Proteomics Unit, Clinical Neuroproteomics Group, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, 31008 Pamplona, Spain.
  • Fernández-Puente P; Grupo de Investigación de Reumatología (GIR), Agrupación CICA-INIBIC, Universidad de A Coruña, A Coruña, Spain.
  • Fidalgo MJ; ProteoRed-ISCIII, Scientific and Technological Centers (CCiTUB), University of Barcelona, 08036 Barcelona, Spain.
  • Froment C; Proteomics and Mass Spectrometry of Biomolecules, Proteomics Infrastructure of Toulouse, Proteomics French Infrastructure, ProFI. Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, UPS, CNRS, Toulouse, France.
  • Fuentes M; Department of Medicine and General Cytometry Service-Nucleus, Proteomics Unit, CIBERONC, Cancer Research Center (IBMCC/CSIC/USAL/IBSAL), Universidad de Salamanca, Spain.
  • Fuentes-Almagro C; Proteomics Unit, SCAI, University of Córdoba, Ramón y Cajal Building, Rabanales Campus, 14071, Córdoba, Spain.
  • Gay M; ProteoRed-ISCIII, Institute for Research in Biomedicine (IRB Barcelona), BIST (The Barcelona Institute of Science and Technology), Baldiri i Reixac 10, 08028 Barcelona, Spain.
  • Hainard A; Proteomics Core Facility, CMU, University of Geneva, Switzerland.
  • Heller M; Department for BioMedical Research (DBMR), Proteomics and Mass Spectrometry Core Facility, University of Bern, CH-3010 Bern, Switzerland.
  • Hernández ML; ProteoRed-ISCIII, Proteomics Unit, Complutense University, 28040 Madrid, Spain.
  • Ibarrola N; ProteoRed-ISCIII, Proteomics Unit. Cancer Research Center (IBMCC/CSIC/USAL/IBSAL), Universidad de Salamanca-CSIC, Salamanca, Spain.
  • Iloro I; ProteoRed-ISCIII, CIC bioGUNE, Proteomics Platform, Basque Research & Technology Alliance (BRTA), CIBERehd,Bizkaia Science and Technology Park, 48160 Derio, Spain.
  • Kieselbach T; Umeå University, Department of Chemistry, 90187, Umeå, Sweden.
  • Lario A; ProteoRed-ISCIII, IPBLN -CSIC, 18016 Granada, Spain.
  • Locard-Paulet M; Proteomics and Mass Spectrometry of Biomolecules, Proteomics Infrastructure of Toulouse, Proteomics French Infrastructure, ProFI. Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, UPS, CNRS, Toulouse, France.
  • Marina-Ramírez A; ProteoRed-ISCIII, CBM Severo Ochoa (CSIC-UAM), Madrid 28049, Spain.
  • Martín L; ProteoRed-ISCIII, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.
  • Morato-López E; ProteoRed-ISCIII, CBM Severo Ochoa (CSIC-UAM), Madrid 28049, Spain.
  • Muñoz J; ProteoRed-ISCIII, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
  • Navajas R; ProteoRed-ISCIII, Centro Nacional de Biotecnologia (CSIC), 28049, Madrid, Spain.
  • Odena MA; ProteoRed-ISCIII, Proteomics Platform, Barcelona Science Park, 08028, Barcelona, Spain.
  • Odriozola L; ProteoRed-ISCIII, CIMA, University of Navarra, 31008, Pamplona, Spain.
  • de Oliveira E; ProteoRed-ISCIII, Proteomics Platform, Barcelona Science Park, 08028, Barcelona, Spain.
  • Paradela A; ProteoRed-ISCIII, Centro Nacional de Biotecnologia (CSIC), 28049, Madrid, Spain.
  • Pasquarello C; Proteomics Core Facility, CMU, University of Geneva, Switzerland.
  • de Los Rios V; ProteoRed-ISCIII, Centro de Investigaciones Biológicas-CSIC, Madrid 28040, Spain.
  • Ruiz-Romero C; Grupo de Investigación de Reumatología (GIR) - ProteoRed-ISCIII, Unidad de Proteómica, INIBIC-Complejo Hospitalario Universitario de A Coruña, SERGAS, A Coruña, Spain.
  • Sabidó E; Proteomics Unit, Center for Genomics Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; ProteoRed ISCIII, Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain.
  • Sánchez Del Pino M; Biotechnology and Biomedicine Interdisciplinary Research Unit (ERI BIOTECMED), University of Valencia, 46100 Burjassot, Spain.
  • Sancho J; ProteoRed-ISCIII, IPBLN -CSIC, 18016 Granada, Spain.
  • Santamaría E; Proteored-ISCIII. Proteomics Unit, Clinical Neuroproteomics Group, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, 31008 Pamplona, Spain.
  • Schaeffer-Reiss C; Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.
  • Schneider J; Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.
  • de la Torre C; ProteoRed-ISCIII, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Valero ML; ProteoRed-ISCIII, Proteomics Unit, Central Service for Experimental Research (SCSIE), University of Valencia, 46100, Burjassot, Spain.
  • Vilaseca M; ProteoRed-ISCIII, Institute for Research in Biomedicine (IRB Barcelona), BIST (The Barcelona Institute of Science and Technology), Baldiri i Reixac 10, 08028 Barcelona, Spain.
J Proteomics ; 251: 104409, 2022 01 16.
Article in En | MEDLINE | ID: mdl-34758407
ABSTRACT
Global analysis of protein phosphorylation by mass spectrometry proteomic techniques has emerged in the last decades as a powerful tool in biological and biomedical research. However, there are several factors that make the global study of the phosphoproteome more challenging than measuring non-modified proteins. The low stoichiometry of the phosphorylated species and the need to retrieve residue specific information require particular attention on sample preparation, data acquisition and processing to ensure reproducibility, qualitative and quantitative robustness and ample phosphoproteome coverage in phosphoproteomic workflows. Aiming to investigate the effect of different variables in the performance of proteome wide phosphoprotein analysis protocols, ProteoRed-ISCIII and EuPA launched the Proteomics Multicentric Experiment 11 (PME11). A reference sample consisting of a yeast protein extract spiked in with different amounts of a phosphomix standard (Sigma/Merck) was distributed to 31 laboratories around the globe. Thirty-six datasets from 23 laboratories were analyzed. Our results indicate the suitability of the PME11 reference sample to benchmark and optimize phosphoproteomics strategies, weighing the influence of different factors, as well as to rank intra and inter laboratory performance.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteome / Proteomics Type of study: Clinical_trials / Qualitative_research Language: En Journal: J Proteomics Journal subject: BIOQUIMICA Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proteome / Proteomics Type of study: Clinical_trials / Qualitative_research Language: En Journal: J Proteomics Journal subject: BIOQUIMICA Year: 2022 Document type: Article Affiliation country: